Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, has reported its financial results for 2019 on Tuesday.

The company reported GAAP net income of USD523.4m, or USD9.09 per diluted share in 2019, compared to USD447.1m or USD7.30 per diluted share in 2018.

The firm posted total revenues of USD2,161,761 in 2019 compared to USD1,890,922 in the year-ago period.

Bruce Cozadd, chairman and chief executive officer Jazz Pharmaceuticals, said, 'With more than USD2bn of revenue and double-digit top- and bottom-line growth, we delivered strong 2019 financial results while making significant investments to support the continued robust evolution of our business. Strong execution of our long-term sustainable growth strategy has led to six major product approvals in the past four years, and we look forward to further diversification of our revenue base through corporate development activities and by delivering on other key priorities, including the European launch of Sunosi, the anticipated US launches of lurbinectedin and JZP-258, and pre-launch activities for JZP-458.'